RE: RE: Albiglutide Scott,
Is this the one? (I cut the B.S.!)
1. Informations available.Let's start with the partners page, and crossed the informations with the news release.
- Abraxis ( Plasma Proteins)
- Kedrion (Hyperimmune)
- Macopharma (p-Capt)
- Blue Blood (plasma derived meds)
- Octapharma (Octaplas LG)
- Allist (PBI-1402 and 4419).
- Menarini (???) not a major global pharma.
- Pfizer (??? rich pipeline)
- Atoll (???) small german biotech. Can't see a phase III pipeline, not a major global pharma
- Serono (??? acquired by merck) nothing in their phase III pipeline fits with PLI.
- Zymogenetics (??? Acquired by Bristol myers)
- AM-Pharma (??? not a major global pharma)
- GSK (??? NR in 2004 for ligands)
- Novozyme (Albumine purification)
- Novo Nordisk (interesting pipeline, not sure it's a major global one)
- Halozyme (affinity adsorbant)
- Sartorius (equipment supplier)
- Novartis (ligand for vaccine purification)
- Darier (PBI-1308)
- WIBP (Wuhan)
- Boehringer( ???interesting pipeline)
- Celgene ( ligands)
- Hemcom (medical device)
So it narrow the possibility with Pfizer, GSK and Boehringer, that could have the pipeline. After a few google search, I ended up with an interesting document from Novozyme:
https://www.biopharma.novozymes.com/en/information-centre/posters-and-presentations/Documents/Peptalk_2011_Novel_strategies_for_peptide_formulation_and_drug_delivery_DSEE%5b1%5d.pdf
Take a look on the slides 21, 22, 24, and 27. Albupure is used for the drug Syncria,(albiglutide), and the dates for the phase III trial on slide 27 match the PLI nr.
I can't confirmed this is it, but if it's the case, look at the clinical trial results of Albiglutide of April, and the fact that GSK made an attempt of an hostile take over on Human Genome (They made a licence with GSK for it) could make it an interesting story.
I'm just making speculation here, but time will tell.